ArticleBMC health services research2023

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer.

Jiao Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.